X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5019) 5019
Book Chapter (25) 25
Publication (4) 4
Government Document (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Newspaper Article (2) 2
Streaming Video (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3123) 3123
humans (2792) 2792
immunotherapy (2242) 2242
animals (1811) 1811
immunology (1731) 1731
oncology (1725) 1725
ctla-4 (1543) 1543
cancer (1518) 1518
melanoma (1236) 1236
mice (1136) 1136
ctla-4 blockade (1128) 1128
female (1107) 1107
ipilimumab (1037) 1037
ctla-4 antigen (1030) 1030
male (988) 988
lymphocytes (977) 977
ctla-4 protein (902) 902
t cells (898) 898
lymphocytes t (825) 825
tumors (786) 786
immune checkpoint (711) 711
expression (705) 705
antigens (704) 704
pd-1 (695) 695
antibodies, monoclonal - therapeutic use (693) 693
metastatic melanoma (673) 673
ctla-4 antigen - immunology (653) 653
ctla-4 antigen - antagonists & inhibitors (648) 648
blockade (627) 627
care and treatment (614) 614
t-lymphocytes - immunology (587) 587
middle aged (582) 582
immunotherapy - methods (553) 553
cytotoxicity (545) 545
t-cells (534) 534
neoplasms - immunology (529) 529
antigens, cd (522) 522
nivolumab (512) 512
abatacept (510) 510
dendritic cells (500) 500
pd-1 blockade (500) 500
regulatory t-cells (489) 489
research (480) 480
activation (472) 472
adult (470) 470
metastasis (468) 468
medicine, research & experimental (457) 457
immune system (451) 451
apoptosis (448) 448
programmed cell death 1 receptor - antagonists & inhibitors (444) 444
aged (435) 435
pd-1 protein (435) 435
mice, inbred c57bl (433) 433
chemotherapy (426) 426
patients (426) 426
immune response (422) 422
therapy (418) 418
melanoma - drug therapy (394) 394
chemical and pharmacologic phenomena (389) 389
immunoconjugates (389) 389
neoplasms - therapy (387) 387
analysis (378) 378
health aspects (376) 376
cancer therapies (370) 370
clinical trials (367) 367
autoimmunity (358) 358
antineoplastic agents - therapeutic use (356) 356
t-lymphocytes, regulatory - immunology (353) 353
treatment outcome (353) 353
cell biology (351) 351
antitumor immunity (346) 346
programmed cell death 1 receptor - immunology (346) 346
in-vivo (344) 344
survival (343) 343
antibodies (342) 342
antigens, cd - immunology (340) 340
mice, inbred balb c (340) 340
review (340) 340
t cell receptors (335) 335
pembrolizumab (332) 332
antigens, differentiation - immunology (331) 331
cytokines (326) 326
pd-l1 (321) 321
lymphocyte activation (319) 319
melanoma - immunology (313) 313
ligands (312) 312
gene expression (310) 310
mutation (306) 306
open-label (304) 304
cd28 (300) 300
biomarkers (299) 299
metastases (299) 299
ctla-4 antigen - metabolism (298) 298
cd8-positive t-lymphocytes - immunology (294) 294
immunity (291) 291
monoclonal antibodies (291) 291
multidisciplinary sciences (291) 291
transplantation (284) 284
flow cytometry (282) 282
pd-l1 protein (275) 275
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4986) 4986
French (31) 31
German (29) 29
Japanese (13) 13
Polish (5) 5
Chinese (2) 2
Spanish (2) 2
Hebrew (1) 1
Hungarian (1) 1
Korean (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 359, Issue 6382, pp. 1350 - 1355
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 362, Issue 6411, pp. eaar3593 - 197
Programmed cell death protein–1 (PD-1) and programmed cell death ligand–1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond... 
CELL LUNG-CANCER | MISMATCH-REPAIR DEFICIENCY | MUTATIONAL PROCESSES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MULTIDISCIPLINARY SCIENCES | COPY NUMBER | PROGRAMMED DEATH LIGAND-1 | SEQUENCING DATA | CLINICAL-RESPONSE | SOMATIC MUTATIONS | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Monoclonal antibodies | Genetic aspects | T cells | Biological markers | Gene expression | Cancer | Tumors | Apoptosis | Cell receptors | Physiological aspects | Diagnosis | Identification and classification | Methods | PD-1 protein | Genomics | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Data bases | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Lymphocytes | Deoxyribonucleic acid--DNA | Medical research | Stability | Microsatellites | Mortality | Melanoma | Data processing | Inflammation | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2019, Volume 116, Issue 20, pp. 9999 - 10008
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 18, pp. 1749 - 1755
Journal Article
Nature (London), ISSN 1476-4687, 2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Antibodies, Monoclonal, Humanized | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Cancer discovery, ISSN 2159-8290, 2018, Volume 8, Issue 9, pp. 1069 - 1086
Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community to begin to envision potentially curative therapeutic approaches... 
CTLA-4 COUNTER-RECEPTOR | TERTIARY LYMPHOID STRUCTURES | FC-GAMMA RECEPTORS | DENDRITIC CELLS | ONCOLOGY | LONG-TERM SURVIVAL | REGULATORY T-CELLS | FACTOR RECEPTOR SUPERFAMILY | COSTIMULATORY MOLECULE | CANCER-IMMUNOTHERAPY | CUTTING EDGE
Journal Article